

K063652 pag 1/3

**Section 5 – 510 (k) Summary**

(As required by 21 CFR 807.92(c) and 21 CFR 807.93)

**NAME OF SPONSOR:** DePuy Orthopaedics, Inc. FEB - 1 2007  
700 Orthopaedic Drive  
Warsaw, Indiana 46582  
Establishment Registration Number: 1818910

**510(K) CONTACT:** Rebecca Lennard  
Regulatory Affairs Associate II  
Telephone: (574) 372-5023  
Facsimile: (574) 371-4987  
Electronic Mail: [RLennard@dpyus.jnj.com](mailto:RLennard@dpyus.jnj.com)

**ALTERNATE 510(K) CONTACT:** Natalie Heck  
Manager, Regulatory Affairs  
Telephone: (574) 372-7469  
Facsimile: (574) 371-4987  
Electronic Mail: [NHeck@dpyus.jnj.com](mailto:NHeck@dpyus.jnj.com)

**DATE PREPARED:** August 16, 2006

**PROPRIETARY NAME:** DePuy Global AP™ Porous Coated Humeral Stem

**COMMON NAME:** Shoulder Prosthesis

**CLASSIFICATION:** Class II Device per 21 CFR 888.3670: Shoulder joint metal/polymer/metal nonconstrained or semi-constrained porous-coated uncemented prosthesis  
  
Class II Device per 21 CFR 888.3660: Shoulder joint metal/polymer semi-constrained cemented prosthesis

**DEVICE PRODUCT CODE:** 87 MBF  
87 KWS

**SUBSTANTIALLY EQUIVALENT DEVICE:** DePuy Global AP™ Shoulder System, K060874  
Global® Advantage Shoulder Humeral Stem with Porocoat®, K011047

0000013

**DEVICE DESCRIPTION:**

The subject Global AP™ humeral stems are made from titanium alloy and are porous-coated with commercially pure titanium. The stems are available in six sizes. They are identical in design to the Global AP™ Humeral Stems cleared in K060874 on June 28, 2006 with the addition of Porocoat® porous coating applied to the proximal portion of the stem.

**INTENDED USE AND INDICATIONS:****Intended Use:**

The subject humeral stem is designed for use as the portion of the shoulder prosthesis that replaces the proximal humerus upon which a prosthetic humeral head is attached to articulate with the natural glenoid fossa or a prosthetic glenoid replacement. The DePuy Global AP™ Porous Coated Humeral Stems are intended for cemented or cementless use, with fixation provided by biological tissue ingrowth into the porous coating.

**Indications for Use:**

Total Shoulder or hemi-shoulder replacement is indicated for:

1. A severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis.
2. Fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory.
3. Other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. revision of a failed primary component).

The humeral components of the Global AP™ Shoulder are intended for cemented or cementless use as a total or hemi-shoulder replacement.

Global AP™ Porous Coated Humeral Stems are intended for cemented or cementless use, with fixation provided by biological tissue ingrowth into the porous coating.

Glenoid components of the Global AP™ Shoulder are indicated only for use with bone cement for the above indications.

Hemi-shoulder replacement is also indicated for:

1. Ununited humeral head fractures;
2. Avascular necrosis of the humeral head.
3. Deformity and/or limited motion.

**BASIS OF SUBSTANTIAL EQUIVALENCE:**

The DePuy Global AP™ Porous Coated Humeral Stem is substantially equivalent to the previously cleared DePuy Global AP™ Shoulder System (K060874) and the Global® Advantage Shoulder Humeral Stem with Porocoat® (K011047) based upon intended use, indications for use, design, materials, packaging and sterilization. The subject device does not raise any new issues of safety or effectiveness.



DePuy Orthopaedics, Inc.  
% Ms. Rebecca Lennard  
Regulatory Affairs Associate II  
700 Orthopaedic Drive  
Warsaw, Indiana 46582

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

FEB - 1 2007

Re: K063652

Trade/Device Name: DePuy Global AP™ Porous Coated Humeral Stem  
Regulation Number: 21 CFR 888.3670  
Regulation Name: Shoulder joint metal/polymer/metal non-constrained or semi-constrained porous-coated uncemented prosthesis  
Regulatory Class: Class II  
Product Code: MBF, KWS  
Dated: December 7, 2006  
Received: December 8, 2006

Dear Ms. Lennard:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Rebecca Lennard

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or 240-276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson". The signature is written in a cursive style with a large initial "M".

Mark N. Melkerson

Director

Division of General, Restorative

and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

